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Abstract Breast cancer is a major public health problem.
Despite remarkable advances in early diagnosis and treat-
ment, one in three women may have metastases since
diagnosis. Better understanding of prognostic and predic-
tive factors allows us to select the most appropriate adju-
vant therapy in each patient. In these guidelines, we
summarize current evidence for the medical management
of early-stage breast cancer.
Keywords Early-stage breast cancer  Clinical
guidelines  Adjuvant  Neoadjuvant  Genomic platforms
Introduction
Breast cancer is a major public health problem due to its
high incidence, prevalence, and mortality. It is by far the
most common cancer among women in Spain (2012),
accounting for 29 % of all new cases of cancer in
females. Moreover, it is the first cause of cancer-related
mortality in the female population, accounting for 15.5 %
of female cancer deaths, and the 5-year prevalence is
31.4 % [1].
Breast cancer is a heterogeneous disease with multiple
intrinsic tumor subtypes [2]. Up to one in three patients
will develop metastases during the disease depending on
lymph node involvement and breast cancer subtype, despite
remarkable progress in early diagnosis and treatment [3]. A
better understanding of prognostic and predictive factors is
allowing to individualize the treatment of early-stage breast
cancer patients. The aim of these guidelines is to summa-
rize current evidence and to give evidence-based recom-
mendations for clinical practice.
Methodology
These SEOM Guidelines have been developed with the
consensus of ten breast cancer oncologists from the coop-
erative groups GEICAM (Spanish Breast Cancer Research
Group) and SOLTI (Spanish Collaborative Group for the
Study, Treatment and Other Experimental Strategies in
Solid Tumors). To assign a level of evidence and a grade of
recommendation to the different statements of this treat-
ment guideline, it was decided to use the Infectious Dis-
eases Society of America-US Public Health Service
Grading System for Ranking Recommendations in Clinical
Guidelines to determine the quality of evidence and
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strength of recommendation in each of the consensus rec-
ommendations (Table 1).
Diagnosis and initial workup
The following tests allow for a correct diagnostic and
prognostic approach to all patients in whom the presence of
a breast tumor is suspected.
– Mammography and ultrasound: Initial imaging test
which also permits a biopsy to be taken of suspicious
lesions [I, A].
– Core biopsy: essential for diagnosis and to obtain
prognostic information. It is essential to study the
estrogen receptor, progesterone receptor, and HER2.
Ki-67 determination has high inter-observer variability
and care should be taken when using Ki67 to inform the
decision-making process [I, A] [4].
– MRI: allows for better staging of the disease by
detecting disease foci not visible by other methods.
Additional findings must be confirmed histologically
due to the rate of false positives. Use of MRIs has not
shown a survival benefit, and therefore, it is not
considered a mandatory test [I, B] [5]. It should be used
in case of nodal carcinoma or Paget’s disease without
lesion identifiable in mammogram or ultrasound. It can
be useful prior and after neoadjuvant treatment to
define the extent of disease and monitor the response to
treatment.
– Additional studies: anamnesis, complete physical
examination, lab test with complete blood count, liver
and renal function, alkaline phosphatase and calcium.
When anomalies are detected in these tests, or when
disease is detected at advanced stage (stage III), a more
extensive study is performed using PET-CT or
thoracic-abdominal CT and bone scan (if bone symp-
toms, elevation of alkaline phosphatase, LDH, or
calcium are present) [I, B] [6].
Principles of surgery in early-stage breast cancer
Breast-conserving surgery based on lumpectomy is equiv-
alent to mastectomy and must be considered as first option
in most cases of stages I–II [Level of evidence, Grade of
recommendation A] [7, 8]. Lumpectomy is not indicated in
case of diffuse disease in the breast, and in cases with
positive margins when re-excision shows residual disease
or it can not be performed with adequate cosmetic results.
Additionally, other relative contraindications for
lumpectomy are previous radiation therapy in the breast,
active connective diseases with skin involvement, or
tumors with diameter greater than five cm when neoadju-
vant treatment is not indicated or has been not effective.
Radiation therapy during pregnancy is contraindicated, so
mastectomy must be considered if locoregional treatment
must be completed before childbirth.
When mastectomy is performed, contralateral mastec-
tomy as a prophylactic procedure is not indicated in most
of the patients. Younger women, in which BRCA muta-
tions are more common, can benefit most from this strat-
egy. However, decision of contralateral mastectomy must
be considered only after an adequate process of counseling
and discussion of risk–benefit [9].
Sentinel lymph node (SLN) mapping is recommended
for assessment of the involvement of axillary lymph nodes
and should be performed in patients with clinically nega-
tive axillary nodes (Level of Evidence I, Grade of recom-
mendation A). In patients with clinically positive axillary
nodes, pathologic confirmation must be done by fine needle
Table 1 Strength of






A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation
D Moderate evidence to support a recommendation against use
E Good evidence to support a recommendation against use
Quality of evidence
I Evidence from C1 properly randomized, controlled trial
II Evidence from C1 well-designed clinical trial, without randomization; from cohort or case-
controlled analytic studies (preferably from[1 center); from multiple time series; or from
dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical experience, descriptive
studies, or reports of expert committees
940 Clin Transl Oncol (2015) 17:939–945
123
aspiration (FNA) or core biopsy to confirm pathologic
involvement.
Axillary lymph node dissection (ALND) is indicated in
patients with positive SLN biopsy or confirmed preopera-
tive pathologic axillary lymph node involvement. How-
ever, in patients with stage I-II disease and less than three
positive axillary nodes after SLN biopsy and lumpectomy
(and adjuvant radiotherapy indicated), ALND can be
avoided without significant negative impact in DFS and OS
when an adequate postoperative treatment is provided [I,
A] [10].
Regarding SLN biopsy in patients receiving treatment
with neoadjuvant (primary systemic) therapy, ALND is
recommended for cases with pathologically confirmed
axillary lymph node involvement by FNA or core biopsy
before neoadjuvant treatment. In patients with clinically
positive axillary nodes before neoadjuvant and negative
SLN biopsy after chemotherapy, the rate of false negative
is higher than 10 % and ALND is recommended as stan-
dard procedure. However, some studies indicated that for
these patients, when at least three sentinel nodes are
identified and all of them are negative, ALND can be
avoided (Level of evidence II, Grade of recommendation
B). For cases with clinically negative axillary nodes, SLN
biopsy can be performed before or after neoadjuvant
treatment [11].
Principles of adjuvant systemic therapy. Genomic
profiles in decision-making in systemic adjuvant
treatment
Systemic adjuvant treatment is commonly used in early
breast cancer with the intention to reduce the rate of
locoregional or systemic relapses a death derived from the
disease. Unfortunately, treatment decisions are based on
statistical models in which patients have indirect estima-
tions of the risk of relapse and death, and therefore of the
potential benefits of implementing adjuvant strategies.
Multigenic tests provide information beyond standard
clinical and pathologic prognostic factors that can help in
making treatment decisions in ER-positive breast cancer.
All of these tests have been validated for prognosis in year
1–5, but there are some differences, especially beyond
5 years and regarding predicting usefulness of
chemotherapy. We reviewed validation studies of the most
commonly used tests in our country with level of evidence
according to Simon et al. [12].
Oncotype DX. It has been validated for predicting risk
of distance recurrence to 10 years in breast cancer patients
treated with hormone therapy. Oncotype has also proved
predictive value of the benefit of chemotherapy in two
randomized studies (NSABP B-20 and SWOG) [13–15]. In
the German prospective study Plan B, high-risk patients
according to classical clinicopathological factors, in case of
positive ER, and 0–3 nodes and RS of 11 or less, were
treated with hormone therapy alone; results recently pre-
sented showed a 3 years event-free survival of 98.3 %, in
spite of features of high risk by the traditional parameters
[16]. In a recently report, based on studies NSABP B-28
and B-14, RS was associated with 5–15 years distant
relapse risk in 86 % of patients, who had expression of RE
greater than 0.9 [17]. Recently, a prospectively conducted
study concluded that ER?, HER2- N0 patients with tumors
that had a favorable gene expression profile had very low
rates of recurrence at 5 years with endocrine therapy alone
[18]. Level of evidence: IA for the prediction of adjuvant
chemotherapy benefit in low risk group patients. IB for the
prediction of the risk of distant recurrence at 10 years and
benefit of adjuvant chemotherapy in the other ER-positive,
HER2-negative groups.
PAM50 ROR. The PAM50 gene signature classify a
tumor as one of four intrinsic subtypes (Luminal A,
Luminal B, HER2-enriched, and Basal-like), which have
been shown to be prognostic in both untreated and
tamoxifen-treated patient populations. PAM50 estimates
patient’s probability of disease recurrence by weighting the
molecular subtype correlations, a subset of proliferation
genes, and pathologic tumor size [19, 20]. PAM50 ROR
score has clearly demonstrated its prognostic value beyond
5 years and added significant prognostic information
beyond the Oncotype RS in ER-positive, postmenopausal
patients treated with endocrine therapy alone (from the
ATAC trial) [21]. It has demonstrated additional prognostic
value in node-positive patients for the risk of late recur-
rence on patients from the ABCSG-8 trial [22, 23]. In a
recent report, ROR obtained from core needle biopsy
predicted response to neoadjuvant chemotherapy in hor-
mone-sensitive HER2-negative patients [24]. Level of
evidence: IB for the prediction of the risk of recurrence
10 years away.
Mammaprint: this signature was validated in 295
patients with pT1 or pT2 tumors with pN0 or pN?, with a
median follow-up of 7.8 years, showing a prognostic value.
This prognostic value has been validated in other studies,
including patients with up to 4–9 positive lymph nodes [25,
26]. Level of evidence: IB for prognostic value.
EndoPredict. EPclin (EndoPredict combined with nodal
status and tumor size) was validated in two randomized
phase III trials, showing prognostic value, for year 1-5 and
beyond [27, 28]. Level of evidence: IB for prognostic value.
For patients with ER?/HER2- tumors, multigenic tests
appear to identify a group of very good prognosis patients
for whom, the benefits of chemotherapy are so small that
they do not outweigh the risks. The assays reviewed have
their own individual advantages. Oncotype, Mammaprint,
Clin Transl Oncol (2015) 17:939–945 941
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PAM-50 ROR score, and EndoPredict are useful in pre-
dicting relapse risk for year 1–5. Beyond 5 years Oncotype,
EndoPredict has showed prognostic value. But PAM-50
ROR showed the strongest prognostic value beyond
5 years. Oncotype showed the strongest predictive value of
the benefit of chemotherapy [29].
Systemic treatment for Luminal-type early-stage
breast cancer
Adjuvant endocrine therapy for early-stage breast
cancer
There is robust evidence that endocrine therapy improves
survival of early-stage luminal breast cancer. Therefore,
adjuvant hormonotherapy should be offered to any of these
patients regardless of age, comorbidity, risk, menopausal
status, chemotherapy exposure, expression level of ER,
PgR expression, and/or Her2 status [I, A].
There are several endocrine treatment options. The
choice would be adjusted to menopause status, comorbid-
ity, and the risk of recurrence. There is not a universal
consensus to determine the risk of recurrence. It is assumed
that those patients whose tumors exhibit a high-risk
pathological and/or genotypic profile established by geno-
mic platforms to advise the use of adjuvant chemotherapy
should be considered at high risk of recurrence [III, D].
The standard treatment for premenopausal women is
5 years of tamoxifen (I, A) [30], but other alternatives
should be considered. Extending tamoxifen beyond 5 years
confers a significant reduction in risk of recurrence but
questionable specific mortality at 10 years, according to the
ATLAS and ATTOm studies [31, 32]. Both studies con-
cluded that the benefit is possibly higher in high-risk
tumors but at the cost of greater toxicity [I, B]. Adjuvant
exemestane with ovarian suppression as compared with
tamoxifen plus ovarian suppression significantly reduced
recurrence but did not improve overall survival in high-risk
adjuvant-chemotherapy-treated premenopausal breast can-
cer patients [33]. This combination is an alternative to
tamoxifen for patients at high risk of recurrence, at the cost
of greater toxicity [I, B].
EBCTCG and SOFT trials support that adjuvant
tamoxifen with GnRH analogues is not better but more
toxic than tamoxifen alone. This combination could be
seen as an alternative for high-risk patients who cannot
tolerate the use of aromatase inhibitors [II, B].
The standard treatment for postmenopausal women is an
aromatase inhibitor sometimes during adjuvant treatment.
There is not a better than another inhibitor (I, A).
Tamoxifen is the second choice (II, B). Front line aro-
matase inhibitor therapy should last for 5 years. In
tamoxifen-starting patients, the switch to aromatase inhi-
bitor can be offered after 2–3 years. Aromatase inhibitor
can also be offered beyond 5 years of tamoxifen.
Primary/neoadjuvant therapy for hormone
receptor-positive disease
In locally advanced cancer and large tumors, primary sys-
temic treatment is indicated (I, A). Systemic treatment
(chemotherapy or endocrine therapy) allows to reduce the
extent of surgery. All treatments recommended in the adju-
vant setting (chemotherapy, endocrine therapy, and targeted
therapies) may also be used in the preoperative setting.
If chemotherapy is used, it is recommended to deliver all
the chemotherapy before surgery, without breaks, with the
aim to increase the probability of achieving a pCR, a
proven factor for good prognosis. A sequential regimen of
anthracyclines and taxanes (6–8 cycles) was associated to
increased probability of pCR, and must be recommended
[II, B] [34, 35].
For ER-positive and Her2-negative disease, especially
for lobular subtype or luminal A tumors (less responsive to
chemotherapy), endocrine therapy given for 6 months is a
good option [36]. For postmenopausal women, AIs are
more effective than tamoxifen [I, A] [37, 38]. There are no
trials evaluating the role of neoadjuvant hormonal treat-
ment in premenopausal patients.
Systemic therapy for early-stage triple-negative
breast cancer
Adjuvant treatment for triple-negative disease
Triple-negative breast cancer (TNBC) is a heterogeneous
disease comprising approximately 15 % of all breast can-
cers. With the exception of medullary, adenoid cystic, and
apocrine carcinomas that have a better outcome, TNBCs
have generally an aggressive behavior. Molecular profiling
has demonstrated that TNBC encloses 6 distinct biological
subtypes that reflect a wide heterogeneity in these tumors.
Conventional chemotherapy remains the mainstay of
adjuvant systemic treatment for most patients with early
TNBC. Adjuvant chemotherapy should include an anthra-
cycline and a taxane [I, B]. Nevertheless, women with T1a/
bN0 tumors have an excellent prognosis without
chemotherapy [39]. No adjuvant chemotherapy is recom-
mended in tumors\0.5 cm (pT1a), and for 0.6–1 cm
tumors, it has to be discussed and balanced [III, B]. The
incidence of BRCA mutations is higher among TNBC
patients (approximately 20 %), and 90 % of BRCA1-mu-
tated tumors are TNBC, but there is not a different treat-
ment option for mutated patients, at present [III, C].
942 Clin Transl Oncol (2015) 17:939–945
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Neoadjuvant treatment for triple-negative disease
Neoadjuvant therapy in TNBC leads to pathologic com-
plete response (pCR) rates of 30–40 %, which has been
associated with an excellent prognosis [40]. However, the
majority of TNBC patients do not achieve a pCR and have
a high risk of early relapse and poor prognosis. The use of
platinum-based chemotherapy in TNBC is currently being
evaluated. Neoadjuvant cisplatin monotherapy in BRCA1
mutation-breast cancer patients is highly effective with
pCR rates of 72–83 %. BRCAness and basal-like subtype
may also predict response to DNA-damaging agents.
Two randomized phase II neoadjuvant trials [41, 42] and
a meta-analysis [43] have assessed the addition of carbo-
platin to anthracyclines and taxane-based chemotherapy for
TNBC. In the GeparSixto trial, the addition of carboplatin
significantly increased the pCR rate in TNBC patients
treated with weekly paclitaxel and liposomal doxorubicin
plus bevacizumab. Patients with both a BRCA1/2 and
family history of breast or ovarian cancer had the largest
improvement in pCR. In the CALGB 40603 study, the
addition of carboplatin (at a dose of AUC every 3 weeks), to
weekly paclitaxel followed by AC every 2 weeks, increased
the rate of pCR as well. Nevertheless, the addition of plat-
inum results in added toxicity, and it remains unclear how to
be use them and whether platinum-based chemotherapy can
extend the survival rate of TNBC patients.
Regarding the type of taxane and outcome, an improved
pCR was observed with Nab-paclitaxel compared to sol-
vent-based weekly paclitaxel (43 vs 34 %) in a head to
head phase III neoadjuvant trial. This effect was seen in all
subgroups specially in TNBC patients [44].
Recommendation: Sequential regimens of anthracyclines
followed by taxanes are the standard treatment. The use of
platinum for the neoadjuvant treatment of TNBC is not
currently recommended except for BRCA mutation carriers
or patients with a strong family history of breast cancer [I, A].
Systemic treatment for early-stage HER2-positive
breast cancer
Adjuvant treatment for HER2-positive disease
HER2 receptor is a membrane tyrosine kinase and when
activated affects cell proliferation and survival. HER2
oncogene amplification is the primary pathway of HER2
receptor overexpression and is a major driver of tumor
development and progression in a subset of breast cancers.
The overexpressed HER2 receptor is a valuable therapeutic
target.
Trastuzumab is a humanized monoclonal antibody with
the specificity for the extracellular domain of HER2. The
scientific evidence is definitive to recommend adjuvant
trastuzumab in node-positive and node-negative tumors
sized [1 cm [I, A] [45, 46]. Due to the relatively high
failure risk, even in patients with node-negative tumors
measuring 0.6 to 1.0 cm, it should also be considered,
particularly in ER-negative disease (II, B) [47]. In most
studies, trastuzumab was administered for 1 year. No
additional benefit was demonstrated for 2 year further
administration [I, A] [48].
Due to its cardiotoxicity, trastuzumab should not be
routinely administered concomitantly with anthracyclines
(I, B). Combination with taxanes is safe and has been
demonstrated to be more effective than sequential treat-
ment. Both AC followed by paclitaxel/docetaxel with
trastuzumab for 1 year commencing with the first dose of
taxanes or TCH are preferred regimens [49].
Luminal B HER2-positive tumors are treated with
chemotherapy, endocrine therapy, and trastuzumab. No
randomized data exist to support omission of chemother-
apy in this group. However, in small, node-negative
tumors, combination of single-agent paclitaxel and trastu-
zumab provides excellent results [II B] [50]. Trastuzumab
may also be safely combined with either radiotherapy or
endocrine therapy.
Neoadjuvant treatment for Her2-positive disease
In the neoadjuvant setting, trastuzumab in combination with
chemotherapy (taxane and anthracycline based) has been the
standard treatment for HER2-positive tumors with axillary
involvement or sizedC2 cm [51]. Dual anti-HER2 blockade
has lead to higher rates of pathological complete responses
but with no improvements in long-term outcomes. Dual
antiHER2 blockade associated with chemotherapy
(trastuzumab ? lapatinib, trastuzumab ?pertuzumab) has
led to improvements in the pCR rate when compared with
chemotherapy associated with trastuzumab agent, as shown
in NEOSPHERE study. These data have been key to the
accelerated approval of this combination, still dependent on
the results of an adjuvant confirmatory trial [II B] [52].
Lapatinib–trastuzumab combo did not translate into
improvement in long-term outcomes, either in the adjuvant
or neoadjuvant setting and such a treatment cannot be rec-
ommended [I, A] [53, 54].
Recommendations of adjuvant radiotherapy
Adjuvant radiotherapy (RT) should be performed in the
case of:
– Breast-conserving surgery: external beam whole radi-
ation therapy (WBRT). If four or more nodes are
Clin Transl Oncol (2015) 17:939–945 943
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involved, supra and infraclavicular radiotherapy is
recommended [I, A].
– Mastectomy: chest wall radiation and supra and
infraclavicular nodes with or without internal mam-
mary and axillary nodes in patients with T4, T3 N?
and involvement of four or more nodes [I, A].
– In one to three involved nodes after breast-conserving
surgery, supra and infraclavicular nodal irradiation is
recommended to minimize the risk of recurrence and
potentially improve disease-specific survival [I, B] [55].
– Patients with T1-2 and one to three involved nodes and
T3N0 after mastectomy have an increased risk of a
locoregional recurrence. However, the benefit of adju-
vant RT can be small, and must be discussed with the
radiation oncologist and other risk factors such a high
grade, age, or lymphovascular invasion must be taken
into account [I, B] [56].
Radiotherapy treatment is generally well tolerated, with
minimal toxicity in the medium and long term, with
planning and management methods of treatment introduced
in recent years. In the indications shown, radiation therapy
has proved effective and very relevant in decreasing the
risk of local recurrence and improving breast cancer mor-
tality. Despite these recommendations, it is important to
note that in elderly patients with stage I, specific studies
have not shown improved survival and should therefore be
assessed individually [I, A] [57]. Furthermore, some low-
risk patients treated with conservative surgery could be
spared whole breast RT and receive only partial breast
radiation or intraoperative treatment, although less evi-
dence exists to support this approach
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